About this trial
To evaluate the accuracy of 68Ga-Pentixafor PET-CT in the classification diagnosis of primary aldosteronism concurrent with autonomous cortisol secretion patient, using AVS and/or postoperative remission as the reference standard for classification diagnosis.
Eligibility criteria
Qualifiers
Getting the written informed consent
The clear diagnosis of primary aldosteronism;
Combined with autonomous cortisol secretion, cortisol after 1mg dexamethasone suppression test (DST) ≥50 nmol/l;
Patients who are willing to undergo surgery;
Disqualifiers
PA patients who meet the by-passing AVS criteria [i.e., younger than 35 years old, spontaneous hypokalemia, adrenal CT indicated unilateral low-density adenoma (≥1cm), plasma aldosterone >300pg/ml];
Suspicion of familial hyperaldosteronism or Liddle syndrome. [i.e., age <20 years, hypertension and hypokalemia, or with family history];
Suspicion of pheochromocytoma or adrenal carcinoma;
Patients with actively malignant tumor;
Trial design
Treatments tested in this trial
- 68Ga-Pentixafor PET/CT
Treatment groups
Sponsors and collaborators
Qifu Li
Lead sponsor
Chongqing Medical University
Sponsor institution
The First Affiliated Hospital of Zhengzhou University
Collaborator
The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School
Collaborator
The Third Xiangya Hospital of Central South University
Collaborator
The Affiliated Hospital Of Southwest Medical University
Collaborator